Philippines Health News API

{
    "totalArticles": 106992,
    "articles": [
        {
            "id": "dc9148e765743fcf576554a65c681c04",
            "title": "Face aging rate quantifies change in biological age to predict cancer outcomes",
            "description": "Chronological age predicts cancer survival but does not capture differences in biological aging rates. We apply FaceAge, an artificial intelligence algorithm that predicts biological age from a facial photograph, to serial clinical facial photographs to calculate the Face Aging Rate (FAR; change in FaceAge divided by the time between photographs). We analyze data from 2276 cancer patients receiving radiation therapy, using photographs captured during routine care. Higher FAR is associated with worse overall survival in stratified analyses of cohorts with the following intervals between photographs: short 10-365 days (adjusted hazard ratio [aHR] and 95% confidence interval: 1.25 [1.03-1.51]), mid 366–730 days (aHR: 1.37 [1.00-1.86]), and long 731-1,460 days (aHR: 1.65 [1.22-2.22]) after adjustment for time between photographs, sex, race, and diagnosis. FAR provides additional prognostic information beyond single time-point measures of FaceAge. FAR is a non-invasive prognostic biomarker that captures dynamic changes in biological aging. Chronological age is a known predictor of cancer survival, but it cannot fully capture variations in biological aging rates. Here, the authors introduce Face Aging Rate (FAR) as a non-invasive biomarker that predicts biological age from serial facial photographs using artificial intelligence, which can serve as a prognostic factor in cancer patients.",
            "content": "Aging is a multifaceted biological process characterized by the decline of physiological functions and increased vulnerability to disease and death1. It affects nearly all living organisms and is intricately linked with various diseases, particularly... [30055 chars]",
            "url": "https://www.nature.com/articles/s41467-025-66758-w?error=cookies_not_supported&code=efc06479-0d08-463e-a032-6ca665660c6e",
            "image": "https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-025-66758-w/MediaObjects/41467_2025_66758_Fig1_HTML.png",
            "publishedAt": "2026-04-28T14:54:08Z",
            "lang": "en",
            "source": {
                "id": "7abf0df285fbe93cdccffcc7c4088737",
                "name": "Nature",
                "url": "https://www.nature.com"
            }
        },
        {
            "id": "9e79f3e2743c8d26ad1c6320330f114a",
            "title": "Novo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on Obesity",
            "description": "Analyses of the higher dose of Wegovy® (semaglutide 7.2 mg) and Wegovy® pill (oral semaglutide 25 mg) show how fast and how much sustained weight loss people who responded early to treatment achievedWegovy® (semaglutide 2.4 mg and 7.2 mg) clinical and real-world data exploring its role in managing menopausal symptoms, including weight gain and migraine, and lowering cardiovascular riskData on next-generation obesity pipeline, including the advanced combined amylin and GLP-1 receptor analoguesBagsværd, Denmark, 28 April 2026 - Novo Nordisk will present new clinical data and real-world evidence at the European Congress on Obesity, 12-15 May in Istanbul, Turkey. The full data, 52 abstracts, span Wegovy® (semaglutide 2.4 mg), higher-dose Wegovy® (semaglutide 7.2 mg), Wegovy® pill (oral semaglutide 25 mg), and CagriSema (cagrilintide 2.4 mg/semaglutide 2.4 mg), an investigational first-in-class combination of a GLP-1 receptor agonist and a long-acting amylin analogue.",
            "content": "Analyses of the higher dose of Wegovy® (semaglutide 7.2 mg) and Wegovy® pill (oral semaglutide 25 mg) show how fast and how much sustained weight loss people who responded early to treatment achieved\nWegovy® (semaglutide 2.4 mg and 7.2 mg) clinical a... [8024 chars]",
            "url": "https://www.manilatimes.net/2026/04/28/tmt-newswire/globenewswire/novo-nordisk-to-present-new-data-on-wegovy-women-with-obesity-and-next-generation-weight-loss-treatments-at-european-congress-on-obesity/2330303",
            "image": "https://www.manilatimes.net/manilatimes/uploads/images/2026/04/28/1032799.jpg",
            "publishedAt": "2026-04-28T12:02:14Z",
            "lang": "en",
            "source": {
                "id": "e3ad8bbf7dbe3c3defc56a8393455066",
                "name": "The Manila Times",
                "url": "https://www.manilatimes.net"
            }
        },
        {
            "id": "712f55eeae2b089c8ae3c0191349aea8",
            "title": "Pomegranate Compound May Help Protect Against Heart Disease, Reveals Study",
            "description": "When you eat pomegranate, your body breaks down a major healthy nutrient called punicalagin (PC) into smaller pieces called urolithins that showed the strongest protective effects.",
            "content": "Pomegranate is a nutrient-rich fruit known for its numerous health benefits. It is packed with antioxidants, particularly punicalagins and anthocyanins, which help protect your cells from damage caused by free radicals. It is rich in vitamin C and K,... [2979 chars]",
            "url": "https://www.ndtv.com/health/pomegranate-compound-may-help-protect-against-heart-disease-reveals-study-11420347",
            "image": "https://c.ndtvimg.com/2025-07/o0bbs7pk_pomegranate_625x300_02_July_25.jpg?im=FeatureCrop,algorithm=dnn,width=1200,height=738",
            "publishedAt": "2026-04-28T11:00:34Z",
            "lang": "en",
            "source": {
                "id": "5775709b019bb5c3dae707e7b660f89e",
                "name": "NDTV",
                "url": "https://www.ndtv.com"
            }
        }
    ]
}